Guangzhou Virotech Pharmaceutical

Guangzhou Virotech Pharmaceutical is a Guangzhou-based biopharmaceutical company. The ClinicalTrials.gov registry lists it as lead sponsor of trials of intravenously administered oncolytic virus therapies based on the M1 alphavirus, including VRT106 (M1-c6v1), in advanced solid tumours and gliomas. No company website could be verified, so company facts here are limited to the registry. On ClinicalTrials.gov it is the lead sponsor of 2 trials recorded in OnCo: NCT07093814 (phase 1/2, A Study of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma) and NCT07589257 (phase 2, A Study of VRT106 in Combination With Radiotherapy in Adult Patients With Diffuse Midli...). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.